文献速递重症综合管理与镇静镇痛呼吸衰竭与机械通气

普萘洛尔作为抗焦虑药减少接受机械通气的危重成人镇静剂用量(PROACTIVE):一项开放标签随机对照试验

Propranolol As an Anxiolytic to Reduce the Use of Sedatives for Critically Ill Adults Receiving Mechanical Ventilation (PROACTIVE): An Open-Label Randomized Controlled Trial.
PubMed 文献 · Crit Care Med · 2025-02-21
一句话结论在3家学术医院需大剂量镇静的机械通气患者中,普萘洛尔使镇静剂用量较基线下降54% vs 对照组34%,更多镇静评分达标,死亡与不良事件无差异。

该开放标签随机对照试验在3家学术医院纳入72例接受机械通气且需大剂量镇静的非瘫痪患者,干预组给予肠内普萘洛尔20-60 mg每6小时滴定至效应,所有患者均接受丙泊酚或咪达唑仑的方案化滴定镇静。从基线到第3天24小时镇静剂剂量平均变化干预组为54%、对照组为34%(p=0.048),镇静评估在目标范围内的比例干预组48%、对照组35%(p<0.0001)。死亡率与不良事件无差异。作者认为普萘洛尔是一种廉价药物,在COVID-19大流行期间管理的危重患者中有效降低镇静剂需求,可能有助于在达到目标镇静的同时保存有限的镇静剂供应。

要点

  • 需大剂量镇静的机械通气非瘫痪患者中,从基线到第3天24小时镇静剂剂量平均下降干预组54% vs 对照组34%(p=0.048)。
  • 镇静评估在目标范围内的比例干预组48% vs 对照组35%(p<0.0001)。
  • 干预组接受普萘洛尔平均10天,平均每日剂量90 mg。
  • 死亡率或不良事件无差异。
  • 作者认为普萘洛尔是廉价药物,可能有助于保存有限的镇静剂供应并达到目标镇静。

适用人群与场景

  • 纳入:任何接受机械通气且需要大剂量镇静的非瘫痪患者。
  • 场景:3家学术医院。

处置流程与药物剂量

  • 干预组:肠内普萘洛尔20-60 mg每6小时滴定至效应;所有参与者均接受丙泊酚或咪达唑仑的方案化滴定镇静。

研究设计与关键结果

  • 研究类型:开放标签随机对照试验,3家学术医院,计划纳入72例患者,2021年1月至2022年10月入组。
  • 人群:69%为男性,平均(标准差)年龄54岁(15.91岁);多数因COVID或非COVID肺炎入院。
  • 干预:干预组接受普萘洛尔平均10天(平均每日剂量90 mg);所有参与者接受丙泊酚或咪达唑仑方案化滴定镇静。
  • 主要终点:从基线到第3天24小时镇静剂剂量平均变化,干预组54% vs 对照组34%(p=0.048)。
  • 次要终点:镇静评估在目标范围内的比例干预组48% vs 对照组35%(p<0.0001)。
  • 安全性:死亡率或不良事件无差异。

证据类型、等级与局限

  • 证据类型:开放标签随机对照试验。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为普萘洛尔是一种廉价药物,在COVID-19大流行期间管理的危重患者中有效降低镇静剂需求。
  • 作者认为普萘洛尔可能有助于在达到目标镇静的同时保存有限的镇静剂供应。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVES: Surges in demand for sedatives for mechanical ventilation during the COVID-19 pandemic caused shortages of sedatives globally. Propranolol, a nonselective beta-adrenergic blocker, has been associated with reduced agitation and sedative needs in observational studies. We aimed to test whether propranolol could reduce the dose of sedatives needed in mechanically ventilated patients.

DESIGN: Open-label randomized controlled trial.

SETTING: Three academic hospitals.

SUBJECTS: Any nonparalyzed patient receiving mechanical ventilation and requiring high-dose sedatives.

INTERVENTIONS: Enteral propranolol 20-60 mg every 6 hours titrated to effect in the intervention group; all participants received protocol-titrated sedation with propofol or midazolam.

MEASUREMENTS AND MAIN RESULTS: Mean change in 24 hours dose of sedative from baseline to day 3, proportion of sedation scores within target, and occurrence rate of adverse events. We enrolled a planned 72 patients between January 2021 and October 2022. Sixty-nine percent were male with a mean (sd) age of 54 years (15.91 yr). Most were admitted for COVID or non-COVID pneumonia. Intervention participants received propranolol for a mean of 10 days (mean daily dose, 90 mg). There was a significantly larger decrease in sedative dose from baseline (54% vs. 34%; p = 0.048) and more sedation assessments within target range (48% vs. 35%; p < 0.0001) in the intervention group compared with controls. There were no differences in mortality or adverse events.

CONCLUSIONS: Propranolol is an inexpensive drug that effectively lowered the need for sedatives in critically ill patients managed in the COVID-19 pandemic. Propranolol may help preserve limited supplies of sedatives while achieving target sedation.

来源:Crit Care Med,查看原文。版权归原作者所有。

参考来源

  1. Downar J, Lapenskie J, Kanji S, et al. Propranolol As an Anxiolytic to Reduce the Use of Sedatives for Critically Ill Adults Receiving Mechanical Ventilation (PROACTIVE): An Open-Label Randomized Controlled Trial. Crit Care Med. 2025. PMID: 39982178. doi:10.1097/CCM.0000000000006534

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。